Hepatocellular Carcinoma Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rise in Prevalence of Hepatocellular Carcinoma
   3. Market Restraints
      1. Limited Treatment Options
      2. High Development Costs
   4. Market Opportunities
      1. Increasing Strategic Collaborations
   5. Market Trends
      1. Shift Towards Personalized Medicine
      2. Integration of Immunotherapy
5. MARKET SEGMENTATION
   1. By Drug Class
      1. PD-1/PD-L1 Inhibitors
      2. Atezolizumab (Tecentriq)
      3. Avelumab (Bavencio)
      4. Durvalumab (Imfinzi)
      5. Tyrosine Kinase Inhibitors
      6. Gefitinib
      7. Erlotinib
      8. Sorafenib
      9. Treatment
   2. By Route of Administration
      1. Oral
      2. Injectable
      3. Others
   3. By End User
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
   4. By Distribution Channel
      1. Hospital Pharmacy
      2. Online Pharmacy
      3. Retail Pharmacy
   5. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amgen Inc. (U.S.)
      2. AstraZeneca (U.K.)
      3. Bristol-Myers Squibb Company (U.S.)
      4. Bayer AG (Germany)
      5. CELGENE CORPORATION (U.S.)
      6. Eisai Co., Ltd (Japan)
      7. Exelixis, Inc (U.S.)
      8. F. Hoffmann-La Roche Ltd (Switzerland)
      9. Gilead Sciences, Inc (U.S.)
      10. GSK plc (U.K.)
      11. Hepion Pharmaceuticals (U.S.)
      12. Janssen Global Services, LLC (U.S.)
      13. Lilly (U.S.)
      14. Merck & Co., Inc.(U.S.)
      15. Polaris Group (U.S.)
      16. Pfizer Inc (U.S.)
      17. PROVECTUS BIOPHARMACEUTICALS, INC (U.S.)
      18. SillaJen, Inc (South Korea)
      19. Takeda Pharmaceutical Company Limited (Japan)
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Hepatocellular Carcinomamarket?

The global market of Hepatocellular Carcinoma is projected to reach USD 2.49 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Hepatocellular Carcinomamarket?

The global Hepatocellular Carcinoma market has an estimated annual growth rate of 8.2% .

Q.3. What are the recent trends of Hepatocellular Carcinomamarket?

Shift towards personalized medicine and integration of immunotherapyare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Hepatocellular Carcinoma?

The major companies profiled in this report include Amgen Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), CELGENE CORPORATION (U.S.), Eisai Co., Ltd (Japan), Exelixis, Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc (U.S.), GSK plc (U.K.), Hepion Pharmaceuticals (U.S.), Janssen Global Services, LLC (U.S.), Lilly (U.S.), Merck & Co., Inc.(U.S.), Polaris Group (U.S.), Pfizer Inc (U.S.), PROVECTUS BIOPHARMACEUTICALS, INC (U.S.), SillaJen, Inc (South Korea), Takeda Pharmaceutical Company Limited (Japan), among others.

Q.5. Which region is estimated to held highest CAGR inHepatocellular Carcinomamarket?

North America is estimated to hold biggest share in the market for Hepatocellular Carcinoma.